echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Immunother Cancer: The correlation between body mass index, dosing strategy and the efficacy of immune checkpoint inhibitors

    J Immunother Cancer: The correlation between body mass index, dosing strategy and the efficacy of immune checkpoint inhibitors

    • Last Update: 2021-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The increase in body mass index (BMI) is related to the improved response of many types of cancer to immune checkpoint inhibitors (ICI)
    .
    This study evaluated the correlation between BMI, ICI administration strategy and clinical prognosis

    .

    Body mass index (BMI) and a plurality of types of cancer to increase immune reaction checkpoint inhibitor (ICI) relating to improved immunization

    Researchers extracted clinical data of cancer patients treated with ICI, including age, gender, cancer type, BMI, ICI type, drug delivery strategy (based on weight or fixation), imaging response, overall survival (OS), and progression-free Lifetime (PFS)
    .
    Kaplan-Meier curve, Cox regression and Pearson product-moment correlation coefficient were used to compare the clinical results of low-BMI and high-BMI populations

    .

    A total of 297 patients were recruited, of which 40% were women, and 59% were overweight (BMI ≥ 25)
    .
    204 (69%) patients received a fixed-dose ICI treatment, and 93 (31%) patients received a weight-based ICI dosing regimen

    .

    PFS and OS grouped by BMI

    PFS and OS grouped by BMI

    In the entire cohort, overweight BMI was associated with the improvement of PFS (HR 0.
    69, p=0.
    02) and the trend of OS improvement (HR 0.
    77, p=0.
    08)

    .
    For both endpoints, the prognostic improvement of overweight patients was limited to patients who received weight-based ICI dosing regimens (the HR based on weight vs.
    fixed-dose PFS was 0.
    53[p=0.
    04] vs 0.
    79[p=0.
    2], OS The HRs are 0.
    56[p=0.
    03] vs 0.
    89[p=0.
    54])

    .

    Overweight BMI is associated with the improvement of PFS (HR 0.
    69, p=0.
    02) and the trend of OS improvement (HR 0.
    77, p=0.
    08)

    PFS and OS based on BMI and mode of administration

    PFS and OS based on BMI and mode of administration

    In the multivariate analysis, there was no significant correlation between BMI and PFS or OS
    .
    However,
    the interaction of BMI ≥ 25 and weight-based treatment was related to OS (HR 0.
    50, p=0.
    05), and showed a trend related to PFS (HR 0.
    53, p=0.
    09)

    .

    The interaction of BMI ≥ 25 and weight-based treatment is related to OS (HR 0.
    50, p=0.
    05), and shows a trend related to PFS (HR 0.
    53, p=0.
    09)

    There was no correlation between radiological response and BMI and fixed ICI dose (p=0.
    97), but there was a close to significant trend with weight-based ICI (p=0.
    1)

    .
    In the subgroup analysis, the correlation between BMI, ICI dosing strategy, and clinical prognosis appeared to be limited to men

    .

    In summary, compared with weight-based ICI therapy, patients with BMI<25 often have better results with fixed-dose ICI therapy, while patients with BMI≥25 often have better results with weight-based ICI therapy , although These differences did not reach statistical significance
    .

    Compared with weight-based ICI therapy, patients with BMI<25 often have better results with fixed-dose ICI therapy, while patients with BMI ≥25 often have better results with weight-based ICI therapy.

    Original source:

    Original source:

    Ahmed Murtaza,von Itzstein Mitchell S,Sheffield Thomas et al.
    Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors .
    [J] .
    J Immunother Cancer, 2021, 9: https://doi.
    org/10.
    1136 /jitc-2021-002349

    Association between body mass index, dosing strategy , and efficacy of immune checkpoint inhibitors

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.